German tendering "a fiasco" for industry and health insurers
This article was originally published in Clinica
New regulations for tender issuing in the German medical technical aids sector are causing severe problems for industry, healthcare providers and the statutory health insurance funds. This was the general tone of a MedInform conference, entitled "Tenders in the Medical technical Aids Sector", held last week in Bonn by the medical device industry association, BVMed.
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.